Drug intelligence / Profile preview

GCT-102

Development stage: Unknown
Lead developer: Kidswell Bio
Modality: Stem Cell Therapies → Cell Therapies

Overview

GCT-102 is an investigational cell therapy being developed by Kidswell Bio (formerly Gene Techno Science) and its subsidiary S-Quatre Corporation. The therapy utilizes SQ-SHED, which are stem cells derived from human exfoliated deciduous teeth (SHED). GCT-102 is specifically designed for the treatment of Congenital Entero-Neuropathy, a group of disorders characterized by the absence or dysfunction of nerve cells within the gastrointestinal tract, such as Hirschsprung's disease. The therapeutic approach aims to regenerate or repair the enteric nervous system by leveraging the high proliferative capacity and neurogenic potential of SHED. The development of GCT-102 is being conducted in collaboration with Kyushu University and is currently in early-stage clinical trials.

Other names: SQ-SHED cell therapy

Beyond the preview

Go deeper on GCT-102.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on GCT-102.

Explore the full profile